SCHEMBL17871197

SCHEMBL17871197

CC(CC1(c2ccccn2)NC(=O)NC1=O)C(=O)N1CCN(c2cc(Cl)cc(Cl)c2)[C@@H](C)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ ADAMTS5 Q9UNA0 20/20 1.00
▸ ADAM17 P78536 10/20 1.00
▸ MMP2 P08253 6/20 0.88
▸ MMP14 P50281 4/20 0.76
▸ MMP13 P45452 1/20 0.76
▸ ADAMTS4 O75173 3/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17871200 1.00 ADAMTS5 (1.00) ADAMTS5ADAM17MMP2MMP14MMP13
SCHEMBL22201096 0.95 ADAMTS5 (0.90) ADAMTS5ADAM17MMP2MMP14MMP13
SCHEMBL17871470 0.94 ADAMTS5 (1.00) ADAMTS5ADAM17MMP2MMP14MMP13
SCHEMBL17871261 0.94 ADAMTS5 (1.00) ADAMTS5ADAM17MMP2MMP14MMP13
SCHEMBL17871103 0.92 ADAMTS5 (1.00) ADAMTS5ADAM17MMP2MMP14MMP13
SCHEMBL17871290 0.91 ADAMTS5 (1.00) ADAMTS5ADAM17MMP2MMP14MMP13
SCHEMBL17871299 0.88 ADAMTS5 (1.00) ADAMTS5ADAM17MMP2MMP14MMP13
SCHEMBL17871312 0.87 ADAMTS5 (1.00) ADAMTS5ADAM17MMP2MMP14MMP13
SCHEMBL19691481 0.86 ADAMTS5 (1.00) ADAMTS5ADAM17MMP2MMP14MMP13
SCHEMBL19709548 0.86 ADAMTS5 (1.00) ADAMTS5ADAM17MMP2MMP14MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718588-B2 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis GALAPAGOS NV (BE) 2023-08-08 — — US disclosed
US-20210309614-A1 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS GALAPAGOS NV (BE) 2021-10-07 — — US disclosed
EP-3575294-A1 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS Les Laboratoires Servier (FR) 2019-12-04 — — EP disclosed
US-9926281-B2 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis GALAPAGOS NV (BE) 2018-03-27 — — US disclosed
EP-3237406-A1 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS Galapagos NV (BE) 2017-11-01 — — EP disclosed
WO-2016102347-A1 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS GALAPAGOS NV (BE) 2016-06-30 — — WO disclosed
WO-2016102347-A1 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS GALAPAGOS NV (BE) 2016-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210309614-A1 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS ADAMTS1, ADAMTS5, ADAMTS7 ADAMTS5 2/4885ADAM17 8/4885MMP2 53/4885
US-11718588-B2 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis ADAMTS1, ADAMTS5, ADAMTS7 ADAMTS5 2/4885ADAM17 8/4885MMP2 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback